18 F-FDG PET/CT in staging and metabolic activity assessment of multiple myeloma
10.3760/cma.j.issn.2095-2848.2017.01.009
- VernacularTitle:18 F-FDG PET／CT可用于多发性骨髓瘤临床分期及病灶代谢活性评价
- Author:
Lijuan DI
;
Jianhua ZHANG
;
Rongfu WANG
;
Zhanli FU
;
Yan FAN
;
Xuchu ZHANG
;
Guangyu ZHAO
;
Yonggang CUI
;
Meng LIU
;
Lei KANG
;
Xuhe LIAO
;
Yanfu WANG
- Keywords:
Multiple myeloma;
Neoplasm staging;
Positron-emission tomography;
Tomography,X-ray computed;
Deoxyglucose
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2017;37(1):35-38
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of 18 F?FDG PET/CT in staging multiple myeloma ( MM) and evaluating the glucose metabolic activity of MM. Methods A total of 25 MM patients ( 13 males, 12 females, age:39-67 years) from May 2010 to April 2015 were enrolled in this retrospective study. The SUVmax of each patient was recorded. D?S plus staging according to 18 F?FDG PET/CT was com?pared with the traditional D?S staging. The SUVmax and the percentage of plasmacytes of bone marrow of phase Ⅲ and non?phase Ⅲ ( phaseⅠand Ⅱ) according to D?S plus staging were compared. Two?sample t test and Wilcoxon rank sum test were used to analyze the data. Results In 25 MM patients, the range of SUVmax of lesions was 1.8-12?0 and the mean value was 5.15±2.74. According to D?S staging, the numbers of patients with phase Ⅰ,Ⅱ andⅢwere 7, 4 and 14, respectively. While the numbers were 3, 1 and 21 by D?S plus staging. Based on the D?S plus staging system, stages of 7 patients ( 28%, 7/25 ) were changed. According to the D?S plus staging system, the SUVmax between phaseⅢand non?phaseⅢpatients was significantly different (5.75±2.54 vs 3.00±0?70; t=2.12, P<0.05), while the percentage of plasma?cytes of bone marrow between the 2 groups had no significant difference ( 17. 50%( 4. 25%-41. 75%) vs 11?15%(10.25%-36.57%);z=0.05, P>0.05). Conclusion 18F?FDG PET/CT is of clinical importance for MM staging and metabolic activity assessment of MM.
